• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30

Total: 51 results found.

Page 6 of 6

51. Immunotherapeutics collaborate to develop sonelokimab autoinjector
(Press Releases)
... inflamed tissues and joints. A ~40 kDa molecule, sonelokimab can be delivered subcutaneously by patients via self-injection devices, including in a patient-centric autoinjector format. Sonelokimab is ...